MCL SOX11-negative primary tumors lose B-cell identity and gain in a plasmablast gene signature. (A-B) GSEA analysis on preranked lists. (A) Using our customized gene sets described in “supplemental Materials and methods,” SOX11 upregulated and downregulated genes and primary MCL-SOX11⁺ tumors are enriched for SOX11-upregulated genes whereas primary MCL-SOX11⁻ tumors are enriched in SOX11-downregulated genes. (B) MCL-SOX11⁺ tumors are enriched in B-cell vs plasmablast and PAX5 activated genes gene sets whereas MCL-SOX11⁻ tumors are enriched in plasmablast signature and XBP1 target genes. NES and FDR are shown. Statistical significance is considered when FDR < 0.1. (C) Analysis of CD24 and surface IgM expression in CD19+ CD5+ cells (MCL-SOX11⁺) or CD19+ CD5⁻ cells (MCL-SOX11⁻). Numbers inside the histograms indicate the percentage of positive cells above the isotype control. (D) Mean fluorescence intensity (MFI) of surface CD24 and IgM expression in primary MCL tumors.